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Background: The aim of this study was to describe the computed tomography (CT)-imaging features of renal
epithelioid angiomyolipomas (E-AMLs) to understand and recognize this new category of renal tumors.
Methods: Institutional review board approval was obtained for this retrospective study. Clinical data and preoperative
CT images of 11 cases of E-AML were retrospectively analyzed. All patients had unenhanced and tri-phase dynamic
enhanced CT examination. CT-imaging features including tumor size, existence of fat and calcification, enhancement
degree, enhancement pattern, and enhancement heterogeneity were evaluated.
Results: The patients were ten women and one man. The size of tumor ranged from 1.8 to 10.3 cm. All of them had
distinct edges; one had a lobulated appearance, ten had bulging contour of the involved kidney, and four lesions
had intratumoral fat. Eight of the E-AMLs demonstrated hyper-attenuation, two as iso-attenuation, and one as
hypo-attenuation compared with renal parenchyma on unenhanced CT images. Contrast-enhanced CT features
were markedly heterogeneous in eight cases (73 %). The predominant enhancement pattern was rapid wash-in
to slow wash-out (91 %).
Conclusions: The radiological appearance of most E-AMLs has a tendency to be hyper-attenuated on precontrast
CT with or without fat component and demonstrates a rapid wash-in to slow wash-out dynamic enhancement
pattern.
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Angiomyolipoma (AML) is a histologically complex
mesenchymal tumor composed of varying proportions
of dysmorphic blood vessels, adipose tissue, and spindled
smooth muscle cells [1]. It is a member of the perivascu-
lar epithelioid cell tumor (PEComa) family, which add-
itionally includes lymphangiomyomatosis, clear cell
“sugar” tumor of the lung, and morphologically and
immunohistochemically related tumors at other sites [2].
AML comprises 2.0 to 6.4 % of all renal tumors and is
most commonly benign in behavior [3]. Renal epithelioid
angiomyolipoma (E-AML) is a rare variant of AML,
which is composed of a prominent epithelioid compo-
nent, with spindle and giant cells, and contains none or
a minimal amount of adipose tissue [4]. Unlike classic* Correspondence: yezhaoxiang@163.com
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may exhibit aggressive biology, including local recurrence
and metastasis [5, 6]. Therefore, the current World Health
Organization Classification of Renal Neoplasms regards
E-AML as “a potentially malignant mesenchymal neo-
plasm.” Although the imaging features of classical AML
are well described in the radiology literature, the imaging
appearance of E-AML has been much less well reported
because of the rarity of this entity [5–10]. Herein, we
retrospectively reviewed the imaging findings of E-AML
as obtained using computed tomography (CT).Methods
Patients
Institutional review board approval was obtained at our
institution (Tianjin Medical University Cancer Institute
and Hospital, Tianjin, China) for the present retrospect-
ive study. The requirement for informed consent was
waived. We performed a search of our hospital’sistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu et al. World Journal of Surgical Oncology  (2015) 13:280 Page 2 of 6pathology computer database for cases that occurred be-
tween May 2008 and December 2013 by using the
search terms “nephrectomy,” “renal epithelioid angio-
myolipomas,” and “angiomyolipoma, epithelioid.” We
identified 15 consecutive patients who had undergone
nephrectomy of renal epithelioid angiomyolipomas. The
inclusion criteria were patients who underwent abdominal
CT with unenhanced and tri-phase dynamic contrast en-
hanced within 1 month before surgery. Three patients
who had abdominal CT scans from another hospital and
one patient who had undergone only enhanced CT were
excluded. Finally, 11 patients were enrolled in this study.
The pathological proof of E-AML was obtained by surgi-
cal resection for all cases, and for the present study, E-
AML was defined as tumors that were composed of pre-
dominantly epithelioid cells with abundant cytoplasm,
vesicular nuclei, and prominent nucleoli. Immunohisto-
chemical staining for the antibodies of HMB45, SMA,
vimentin, CD34, and cytokeratin was also used to confirm
the diagnosis in three cases.
CT-scanning protocol
Abdominal CT examinations were performed by using
one of two MDCT systems (Somatom Sensations 64,
Siemens, Erlangon, Germany; High Speed Advantage,
LightSpeed 16, GE, Waukesha, WI, USA). For the 16-
detector scanner, scanning parameters were as follows:
120 kVp; 300–350 mA, pitch of 0.939; and slice thick-
ness of 1.25 mm. For the 64-detector scanner, scanning
parameters were as follows: 120 kVp with tube current
adjusted automatically, pitch of 0.939, and slice thickness
of 1.5 mm. Images were obtained from the top of the
kidneys to pubis. Unenhanced CT scan was performed
before administration of intravenous contrast material
injection, and then, 80–100 ml non-ionic iodine contrast
material (Iohexol, Omnipaque, GE Company, Shanghai,
China) at a concentration of 300 mg iodine/ml was
injected into the antecubital vein at a rate of 2.5 ml/s using
a mechanical injector. Arterial, venous, and delayed-phase
CT was obtained after initiation of intravenous contrast
medium injection, acquired with delay of 28–30, 60–70,
and 120 s, respectively.
Image analysis
All CT images were reviewed by two radiologists, who
were not informed beforehand of the pathologic find-
ings. Decisions on tumor characteristics were reached by
consensus. Tumor size, location, existence of fat and cal-
cification, and enhancement heterogeneity were evalu-
ated. For the detection of fat attenuation, a pixel analysis
was also used for unenhanced CT images. Homogeneity
was defined as being present when more than 90 % of
the area was occupied by the same attenuation value, as
ascertained by visual inspection. Precontrast attenuationwas classified as hypo-attenuation, iso-attenuation, and
hyper-attenuation by comparison with the attenuation of
surrounding renal parenchyma by visual assessment. CT
attenuations of unenhanced, arterial, venous, and delayed-
phase were measured in all cases. The central slice which
could manifest the largest part of tumor was selected then
a region of interest (ROI) was drawn as large as possible
to cover the most solid portion of the tumor, avoiding fat
component, necrotic, or haemorrhagic areas. This proced-
ure was repeated three times, and mean CT attenuation
was obtained by average. The degree of enhancement of
each phase was measured by calculating the difference in
mean attenuation value between the arterial phase and
unenhanced scan, venous phase and unenhanced scan,
and delayed phase and unenhanced scan.
Results
The mean age at presentation of these 11 patients was
48.2 years with a female-to-male ratio of 10:1. None of
the patients are associated with tuberous sclerosis. Pre-
senting symptoms and signs include flank pain and palp-
able abdominal mass in four patients, while others are
all asymptomatic and found incidentally.
Clinical and CT features of all patients were listed in
Table 1. The renal lesions were in the right kidney in
seven cases and the left in four cases. The lesions were
located in the upper renal pole in five cases and lower
renal pole in six cases. The median tumor diameter was
4.4 cm, ranging from a minimum diameter of 1.8 cm to
maximum diameter of 10.3 cm. All of them had distinct
edges; ten of them exhibited exophytic growth, and the
maximum diameter of the tumor was beyond the ex-
pected kidney contour; one case had a lobulated appear-
ance (Fig. 1). Intratumoral fat was identifiable with CT
in four cases, among them one with a large quantity of
fat (Fig. 2) and three with small foci of fat (Fig. 3). None
of them had calcification. Eight cases were hyper-
attenuation, two were iso-attenuation, and one was
hypo-attenuation (Fig. 4) by comparison with the renal
parenchyma on unenhanced CT images. The mass
showed relatively homogeneous enhancement in three
cases, while heterogeneous enhancement in eight cases
(Fig. 4). The CT attenuation increased to different exten-
sions after the injection of contrast medium, and at the
venous phase, the degree of enhancement was greater
than 20 HU for all of them (100 %) and exceeded 60 HU
in eight cases (73 %) compared with unenhanced CT im-
ages. At the delayed phase, the CT attenuation decreased
for ten cases (91 %), while only one case still had a little
increase (Fig. 4). Evaluation of the pattern of dynamic
enhancement revealed that ten lesions were categorized
as “rapid wash-in and slow wash-out” (wash-in enhance-
ment pattern means CT attenuation increases from
unenhanced to arterial and venous phase; wash-out








Unenhanced Arterial phase Venous phase Delayed phase
1 51/F Right/lower 2.1 No No Heterogeneous 41 ± 5.4 94 ± 6.9 106 ± 8.2 80 ± 5.7
2 55/F Left/lower 1.8 No No Heterogeneous 44 ± 6.5 86 ± 5.5 155 ± 9.4 129 ± 8.6
3 45/F Left/lower 6.1 No No Homogeneous 47 ± 6.1 69 ± 7.3 81 ± 7.9 75 ± 6.5
4 23/F Right/upper 2.8 Yes No Heterogeneous 47 ± 5.8 103 ± 8.4 133 ± 9.6 109 ± 8.7
5 41/M Left/upper 4.4 No No Heterogeneous 17 ± 1.7 29 ± 2.3 44 ± 3.5 54 ± 3.2
6 50/F Left/upper 2.1 No No Homogeneous 46 ± 4.7 88 ± 6.3 124 ± 8.5 95 ± 8.2
7 55/F Right/lower 3.3 No No Homogeneous 49 ± 5.9 96 ± 6.8 126 ± 6.1 102 ± 7.4
8 62/F Right/upper 10.3 Yes No Heterogeneous 44 ± 5.6 82 ± 7.3 116 ± 8.9 101 ± 7.8
9 35/F Right/lower 4.9 Yes No Heterogeneous 45 ± 4.8 117 ± 8.2 121 ± 9.5 115 ± 8.5
10 65/F Right/upper 6.8 Yes No Heterogeneous 38 ± 4.1 77 ± 6.0 99 ± 5.4 87 ± 5.2
11 48/F Right/lower 3.8 No No Heterogeneous 43 ± 4.8 69 ± 5.3 83 ± 6.2 76 ± 6.0
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venous to delayed phase) and the other one as progressive
enhancement which was characterized as CT attenuation
increased steadily from the arterial to delayed phase. The
border between the tumor and normal kidney was distinct
in all cases. Additional classical AML could be found in
one case. There was no imaging evidence of lymph node
enlargement and vascular invasion in any of our cases.
The pathological evaluation revealed epithelioid, short
spindle cells with eosinophilic cytoplasm, large and
deeply stained nuclei, and dense arrangement of tumor
cells with patchy necrosis (Fig. 3). ImmunohistochemicalFig. 1 A 45-year-old woman with E-AML. The patient had no clinical symp
Non-contrast axial CT image (a) demonstrates a hyper-density lesion with l
Contrast-enhanced CT images of arterial (b), venous (c), and delayed-phasestudies in three cases demonstrated that the tumor cells
were positive for CD34, vimentin, SMA, and HMB-45,
but negative for S-100 (Fig. 3).
One patient was followed up after surgery for
29 months and no obvious sign of recurrence or metas-
tasis was found on follow-up CT images. Ten patients
did not receive imaging follow-up because the diagnosis
at the time was thought to be benign.
Discussion
E-AML of the kidney occurs predominantly in females
[3, 7, 9, 10], and according to Aydin et al. [3], patientstoms. A renal mass was found during physical examination.
obulated appearance in the lower renal pole of the left kidney.
(d) demonstrate relatively homogeneous enhancement
Fig. 2 Macroscopic fat containing E-AML in a 62-year-old woman. Non-contrast axial CT image (a) demonstrates a slight hyper-density mass
in the right kidney with abundance of fat and large amounts of soft tissue. Contrast-enhanced CT image of venous phase (b) and coronal
reconstruction image of delayed-phase (c) demonstrate heterogeneous enhancement
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(38.6 vs. 52.3 years). In this study, the mean age at pres-
entation was 48.2 (range, 23–65) years, and female-to-
male ratio was 10:1. The differences in the reported
mean age and gender ratio are likely due to the small
number of cases reviewed in these series.
Like other AMLs, E-AMLs can occur in patients both
with and without tuberous sclerosis. One of eight E-
AMLs (12.5 %) described by Tsukada et al. [7] and two
of nine cases (22.2 %) published by Froemming et al. [9]
were seen in patients with tuberous sclerosis complexFig. 3 Minimum fat containing E-AML in a 35-year-old woman. Non-contra
edge. Coronal reconstruction image of delayed-phase (b) demonstrates he
(arrow). Microscopically (c), the tumor is composed of thick-walled blood
magnification ×200). Tumor cells show strong immunoreaction with anti
magnification ×200)(TSC). Tsai et al. [11] found that approximately half of
E-AML cases are associated with the TSC, all contained
minimal to no fat, and all demonstrated a positive reac-
tion to premelanosome antigens (PMAs). Cysts and mul-
tiple AMLs are the most common renal manifestation in
TSC [12, 13]. In our series, only one case had additional
classical AML; however, no evidence of tuberous scler-
osis syndrome was documented.
In contradistinction to typical AMLs which have rela-
tively characteristic imaging findings, E-AMLs often
mimic renal cell carcinoma (RCC), renal sarcoma, orst axial CT image (a) demonstrates a hyper-density mass with distinct
terogeneous enhancement, and small foci of fat could be identified
vessels, adipose tissue, and epithelioid cells (HE staining, original
body to HMB-45 (d) (immunohistochemical staining, original
Fig. 4 A 41-year-old male with an incidentally discovered left-sided renal mass. Axial non-contrast image (a) demonstrates an exophytic mass
with hypo-density arising from the posterior aspect of the left kidney. Contrast-enhanced CT images of arterial (b), venous (c), and delayed-phase
(d) demonstrate progressive heterogeneous enhancement with enlarged blood vessels presented in the lesion
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which may lead to incorrect diagnosis. To date, the im-
aging appearance of E-AML has been much less well re-
ported than the histopathologic features since most of
the imaging findings are individual reports. Tsai et al.
[11] reported that none of the five lesions contained fat
components (<−20 HU) or calcification. He also per-
formed an analysis of the literature since 1998 and found
that no fat component was described in any of the other
15 cases of E-AML with reported imaging findings. In
another study conducted by Tsukada et al. [7], no fat
component was detected on unenhanced CT images,
T1-weighted images, T2-weighted images, or chemical
fat suppression images in any of the eight E-AML cases.
However, in other studies, fat was seen in the tumor at
imaging [9, 14]. In this study, four lesions had compo-
nents of fat identifiable at thin CT images, accounting
for 36 % of all cases, and one of them had a large quan-
tity of fat thus misdiagnosed as AML at preoperative im-
aging diagnosis. Most of the literatures that focused on
imaging findings demonstrated that the characteristic
imaging features of E-AML include higher density (than
normal renal parenchyma) at unenhanced CT, bulging
contour of the affected kidney, markedly heterogeneous
enhancement, large lesion size on presentation, and
complete capsule with distinct edges, occasionally with
regional lymph node metastases [9–11]. All of the cases
in our series had distinct edges; ten of them exhibited
exophytic growth (91 %) and eight of them showedhyper-attenuation (73 %) on unenhanced CT images.
The higher density at unenhanced CT has been as-
cribed to the densely packed epithelioid muscle compo-
nent [15, 16]. The amount of enhancement described
varied among different studies [7, 9, 10]. A recent study
reported E-AMLs can present as heterogeneously or
homogeneously enhancing solid masses or as multilo-
cular cystic masses [7]. In the present study, most of
the lesions showed heterogeneous enhancement (73 %),
among which the presence of enlarged blood vessels
could be seen in two cases, while the others showed
relatively homogeneous enhancement (27 %). The pre-
dominant enhancement pattern is categorized as “rapid
wash-in and slow wash-out,” which is in accordance
with a previous study [10]. This phenomenon is thought
to correlate with pathological descriptions: abundance of
abnormal vessels, higher cellular density and decreased
tumor stroma, presence of complete capsule, and lack of
draining vessels.
The final diagnosis of E-AML will depend on the
histopathological examination, especially immunohis-
tochemistry. E-AML stains strongly for melanoma-
associated markers, particularly HMB-45 (human mel-
anoma, black) and negative for epithelial markers and
S-100. Compared to E-AML, RCCs are positive for
epithelial markers and negative for melanocytic markers
and S-100 [2].
The current World Health Organization Classification
of Renal Neoplasms regards E-AML as “a potentially
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comes in approximately one third of cases. In a recent
meta-analytical study in which 69 well-documented
cases of epithelioid AML in the literature were reviewed,
the malignancy rate was found to be 38 % [17]. However,
given the relatively low number of cases thus far in the
literature and variability in pathologic criteria for desig-
nating a tumor E-AML, the natural course remains un-
certain but suggests that a significant minority of these
tumors act in a malignant manner. In the present case,
one patient was followed up after surgery for 29 months
and no obvious sign of recurrence or metastasis was
found on follow-up CT images.
The present study had several limitations. First, the
number of cases was small. Thus, further evaluations
using a large number of cases from multicenters are ne-
cessary to confirm our findings. Second, there was a lim-
ited spectrum of images available for each patient, and
fat-sensitive imaging techniques, such as chemical shift
suppression images, were not obtained. Finally, most pa-
tients did not receive imaging follow-up because the
diagnosis at the time was thought to be benign.
Conclusions
Most E-AMLs tend to present as a solid lesion with
hyper-density on unenhanced CT with or without fat
component and demonstrate rapid wash-in to slow
wash-out dynamic enhancement pattern. Whenever a
fatty renal mass contains large amounts of soft tissue,
the possibility of E-AML should be included in the dif-
ferential diagnosis.
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